ChatGPT

Perplexity

Gemini

Claude

Grok

McKesson & Healthcare Providers Federal Credit Union Mobile provides members convenient access to our website, mobile check deposit, mobile banking, branch and contact information.

McKesson Authenticator is a free application for Two Factor Authentication (2FA) which generates Time-based One-Time Passcodes (TOTP) and PUSH Authentication. It helps to keep your account secure on s

Welcome to McKesson Canada's Event App.

Download the "McKesson Canada Events" Mobile App to view our current or upcoming events from the convenience of your mobile device. You will receive a unique e

Download the “McKesson Events” App to view our current or upcoming events. You will receive a unique event code to access and view the details of each event. Téléchargez l'application « McKesson Event

McKesson operates with the highest ethical standards, building trust with customers and patients through transparency, accountability, and doing what is right even when difficult. The company's values foundation I²CARE places Integrity first, reflecting its critical importance to the business and its reputation as a trusted healthcare partner.

Integrity

McKesson strives to create and maintain an inclusive culture where everyone feels comfortable bringing their authentic self to work each day. With 11 Employee Resource Groups across North America and recognition as a Best Place to Work for Disability Inclusion and Best Company for Multicultural Women, the company actively fosters belonging and celebrates diversity.

Inclusion

Placing customers and patients at the center of every decision, McKesson delivers pharmaceutical products and services safely, reliably, and on time through a vast physical infrastructure and digitally connected distribution network. The company's customer-first orientation drives continuous improvement and innovation.

Customer-First

McKesson holds itself accountable to customers, partners, employees, and shareholders by executing with discipline, measuring performance rigorously, and taking ownership of results. This accountability extends to quality standards, regulatory compliance, and financial commitments.

Accountability

The company pursues operational excellence across all dimensions of the business, from supply chain efficiency and technology innovation to employee development and customer service. McKesson's ILEAD leadership framework—Inspire, Leverage, Execute, Advance, and Develop—brings out the best in employees and drives superior outcomes.

Excellence

McKesson Corporation is the largest pharmaceutical distributor in North America and the ninth-largest company by revenue in the United States, delivering one-third of all pharmaceutical products used or consumed in North America. With $359.1 billion in fiscal 2025 revenue, McKesson provides pharmaceutical distribution, medical supplies, health information technology, and care management tools to healthcare providers across the continuum of care.

CoverMyMeds gets acquired by McKesson for $1.1bil

BLM activist Deray McKesson victimized by Verizon's customer service backdoor

McKesson: The healthcare tech giant you've probably never heard of

Fast-growing CoverMyMeds to be acquired by McKesson for $1.1B

McKesson Moving HQ from California to Texas

Brian S. Tyler, Ph.D.

Chief Executive Officer & Board Member

Leann Smith

Executive Vice President & Chief Human Resources Officer

Tom Rodgers

Executive Vice President & Chief Strategy and Business Development Officer

Dr. Kelvin Baggett

Chief Impact Officer

McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK". McKesson provides extensive network of infrastructure for the healthcare industry and was an early adopter of technologies, including barcode scanning for distribution, pharmacy robotics, and RFID tags. The company has been named in a federal lawsuit for profiting from the opioid epidemic in the United States.

https://en.wikipedia.org/wiki/McKesson_Corporation

McKesson's largest business segment delivers wholesale drug distribution services across the United States and Canada to retail and community pharmacies, health systems, and institutional healthcare providers. The company distributes branded, generic, and specialty pharmaceuticals safely and reliably through a vast physical infrastructure and digitally connected distribution network spanning North America.

North American Pharmaceutical Distribution

As the #1 distributor of oncology, rheumatology, and gastroenterology products and #2 distributor of ophthalmology and neurology products, McKesson provides end-to-end specialty pharmaceutical distribution services ensuring complex, high-cost therapies reach patients who depend on them. The company is the second-largest specialty drug distributor in the nation.

Specialty Drug Distribution

McKesson provides comprehensive practice management, technology solutions, clinical trial support, and group purchasing services to community-based oncology practices. Practices in The US Oncology Network treat over 15% of all new cancer patients annually, with 700+ clinical trials actively enrolling patients through SCRI (Sarah Cannon Research Institute).

Oncology Practice Management & The US Oncology Network

McKesson distributes medical-surgical supplies, pharmaceuticals, laboratory equipment and supplies to non-acute care settings including physician offices, surgery centers, long-term care providers, laboratories, home health and hospice agencies, health systems, government facilities, and online marketplaces. The company announced plans to separate this segment into an independent company in May 2025.

Medical-Surgical Solutions

InspiroGene by McKesson partners with biopharma companies to solve the complexities of commercializing cell and gene therapy, combining deep expertise, tailored logistics, and comprehensive understanding of every patient and product journey to enable successful advanced therapy commercialization.

InspiroGene Cell & Gene Therapy Solutions

McKesson provides health IT solutions including electronic health records, practice management systems, revenue cycle management, population health analytics, and clinical decision support tools to healthcare providers, payers, and life sciences companies, driving efficiency and improved outcomes through technology.

Health Information Technology

McKesson offers pharmacy technology platforms, pharmacy automation systems, medication adherence programs, and prescription management solutions that help retail and institutional pharmacies optimize operations, reduce errors, improve patient safety, and enhance medication therapy management.

Prescription Technology Solutions

McKesson announced fiscal year 2025 results with consolidated revenues of $359.1 billion, a 16% increase year-over-year, and adjusted earnings per diluted share of $33.05, up 20%. The company generated cash from operations of $6.1 billion and free cash flow of $5.2 billion, demonstrating strong operational execution and financial performance.

McKesson Reports Record Fiscal 2025 Results with 16% Revenue Growth to $359.1 Billion

McKesson announced its intention to separate the Medical-Surgical Solutions segment into an independent, publicly traded company, allowing each business to pursue focused growth strategies. The separation is expected to unlock value for shareholders while enabling both companies to optimize capital allocation and strategic priorities.

McKesson Announces Intent to Separate Medical-Surgical Solutions into Independent Company

McKesson completed the acquisition of an approximate 70% controlling interest in Florida Cancer Specialists & Research Institute's Core Ventures for about $2.49 billion. The acquisition significantly expands McKesson's oncology platform, adding one of the nation's largest community-based oncology networks to the company's Oncology and Multispecialty segment.

McKesson Completes Acquisition of Core Ventures for $2.49 Billion

McKesson completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC, a premier provider of general ophthalmology and retina management services, for approximately $850 million. The transaction advances McKesson's specialty healthcare leadership and expands capabilities in ophthalmology and retina care.

McKesson Completes $850 Million PRISM Vision Holdings Acquisition

McKesson closed the transaction to sell its Canada-based Rexall and Well.ca retail pharmacy businesses to Birch Hill Equity Partners, a Canadian private equity firm. The divestiture allows McKesson to focus on core pharmaceutical distribution and specialty healthcare services while exiting lower-margin retail pharmacy operations.

McKesson Completes Divestiture of Rexall and Well.ca to Birch Hill Equity Partners

McKesson announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new structure includes North American Pharmaceutical, Oncology and Multispecialty, and Medical-Surgical Solutions segments, aligning the organization to drive growth in priority markets and optimize operational efficiency.

McKesson Announces New Organizational Structure with Three Focused Segments

McKesson reported fiscal second quarter 2025 consolidated revenues of $93.7 billion, up 21%, and adjusted earnings per diluted share of $7.07, up 13%. The company raised its full-year fiscal 2025 adjusted EPS guidance to $31.75 to $32.55, reflecting strong operational execution and market demand for pharmaceutical distribution and specialty services.

McKesson Raises Fiscal 2025 Guidance Following Strong Q2 Performance

McKesson fucked up and sent us massive quantities of lotion, test strips and trazodone

UNIONIZE CoverMyMeds/McKesson!

CoverMyMed Layoffs?

Re-shoring antibiotic manufacture: Walmart, McKesson and USAntibiotics partner to produce, distribute amoxicillin

Ford v. McKesson: Divided CA5 panel holds that alleged Black Lives Matter protest leader may be liable for negligence in leading a protest that injured plaintiff police officer and the First Amendment does not protect him from liability, remands for trial

What is the work environment/culture like at McKesson?

McKesson and Cardinal

Does anyone have advice for interviewing at McKesson?

McKesson/ CoverMyMeds

Columbus

careerguidance

PharmacyTechnician

PrepperIntel

supremecourt

stocks

Layoffs

MCKESSON CORP

Wholesale-Drugs, Proprietaries & Druggists' Sundries

John McKesson and Charles Olcott established Olcott & McKesson, a wholesale and import drug company in Manhattan, New York, to provide therapeutic drugs and herbal products to physicians and apothecaries, marking the beginning of what would become America's largest pharmaceutical distributor.

Olcott & McKesson Founded in Manhattan

Following the addition of partner Daniel Robbins and the death of co-founder Charles Olcott in 1853, the company was renamed McKesson & Robbins, a name that would endure for nearly 150 years as the business expanded across the United States.

Company Renamed McKesson & Robbins

McKesson & Robbins became one of the first wholesale drug firms to manufacture pharmaceuticals in addition to distributing them, vertically integrating operations to ensure product quality and capture manufacturing profit margins during the early professionalization of American medicine.

Begins Drug Manufacturing

McKesson & Robbins partially consolidated the pharmaceutical wholesale industry by convincing several large wholesale drug distributors to become McKesson subsidiaries, beginning a century-long pattern of growth through acquisition that would eventually create the modern pharmaceutical distribution oligopoly.

Industry Consolidation Begins

The exposure of a massive accounting fraud under CEO Phillip Musica (alias Frank D. Coster) involving fictitious assets and fake subsidiaries led to one of the biggest business scandals in American history, directly prompting fundamental reforms in American auditing standards including requirements for physical inventory verification.

McKesson and Robbins Scandal Exposed

Foremost Dairies acquired McKesson & Robbins to form Foremost-McKesson Inc., creating a diversified consumer products and pharmaceutical distribution conglomerate. This merger brought significant capital but ultimately proved to be an unsuccessful diversification strategy that was later reversed.

Foremost Dairies Acquisition Creates Foremost-McKesson

The company's name reverted from Foremost-McKesson to simply McKesson Corporation, reflecting a strategic refocusing on pharmaceutical distribution and healthcare services after years of diversification into unrelated consumer products businesses.

Company Name Reverts to McKesson Corporation

McKesson acquired German pharmaceutical wholesaler Celesio in a transformative transaction that created one of the world's largest healthcare companies with over $179 billion in annual revenue, significantly expanding McKesson's international presence and cementing its position as a global pharmaceutical distribution leader.

Celesio Acquisition Creates Global Healthcare Giant

Brian Tyler assumed the CEO role in April 2019 after more than 25 years with McKesson, bringing extensive company knowledge and operational expertise. The company also relocated its headquarters from San Francisco to Irving, Texas, reducing costs and positioning closer to major healthcare markets.

Brian Tyler Becomes CEO; Headquarters Moves to Texas

On January 4, 2024, McKesson acquired Compile, a healthcare data platform that aggregates and integrates data from across the U.S. healthcare system to characterize providers and their patient panels, enhancing McKesson's technology and analytics capabilities.

Compile Acquisition Adds Healthcare Data Platform

McKesson announced an agreement to acquire approximately 70% controlling interest in Florida Cancer Specialists & Research Institute's Core Ventures for about $2.49 billion, significantly expanding the company's oncology platform and specialty pharmaceutical capabilities.

Core Ventures / Florida Cancer Specialists Acquisition Announced

On December 30, 2024, McKesson closed the transaction to sell its Canada-based Rexall and Well.ca retail pharmacy businesses to Birch Hill Equity Partners, a Canadian private equity firm, divesting non-core retail operations to focus on higher-margin pharmaceutical distribution and specialty services.

Divestiture of Rexall and Well.ca

McKesson signed a definitive agreement in February 2025 to acquire an 80% controlling interest in PRISM Vision Holdings, LLC, a premier provider of general ophthalmology and retina management services, for approximately $850 million, completed on April 2, 2025.

PRISM Vision Holdings Acquisition Agreement

McKesson reported fiscal year 2025 consolidated revenues of $359.1 billion (up 16%) and adjusted earnings per diluted share of $33.05 (up 20%), generating free cash flow of $5.2 billion. The company also announced its intention to separate the Medical-Surgical Solutions segment into an independent company.

Record Fiscal 2025 Results; Medical-Surgical Separation Announced

McKesson completed the acquisition of a controlling interest in Core Ventures on June 3, 2025, adding Florida Cancer Specialists & Research Institute's extensive oncology network to McKesson's Oncology and Multispecialty segment and reinforcing the company's position as a leader in specialty pharmaceutical distribution.

Core Ventures Acquisition Completed

McKesson announced changes to its reportable segments and organizational structure effective in the second quarter of fiscal year 2026, creating three focused segments: North American Pharmaceutical, Oncology and Multispecialty, and Medical-Surgical Solutions, aligning the business for continued growth.

New Organizational Structure Announced

For use with the engineering kits “Robotics: Smart Machines”, “Robotics: Smart Machines - Rovers & Vehicles Edition”, and “Robotics: Smart Machines - Tracks & Treads Edition” by Thames & Kosmos.

This

Dreamehome App is to manage Dreame Bot cleaning robots to do your home floor cleaning.

Through the App , you may not only access to advanced functions of your robot for your daily home floor cleaning

The Blue Alliance is a tool to help FIRST Robotics teams scout for, compete at, and relive competitions.

The Blue Alliance app is the easiest way to access all the great content on thebluealliance.co

Hermes Robotics is a San Francisco-based robotics company founded that provides autonomous street sweeping as a service by retro-fitting existing vehicles with autonomous technology. The YC W21 company achieved $1M in revenue in 2024 with a lean team of just 5 employees, raised $125K from Y Combinator plus additional bootstrap funding, and received an M&A offer in April 2025.

McKesson vs Hermes Robotics

McKesson

About

Hermes Robotics

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time